238 related articles for article (PubMed ID: 19289118)
21. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
[TBL] [Abstract][Full Text] [Related]
22. Molecular diagnosis of Huntington's disease in Mexican patients by polymerase chain reaction.
Cisneros Vega B; Alonso Vilatela ME; Yescas Gomez P; Silva Arreola G; Montañez Ojeda C
Arch Med Res; 1996; 27(1):87-92. PubMed ID: 8867374
[TBL] [Abstract][Full Text] [Related]
23. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
Gil JM; Rego AC
Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
[TBL] [Abstract][Full Text] [Related]
24. Upstream stimulatory factor 2 is implicated in the progression of biliary atresia by regulation of hepcidin expression.
Huang YH; Huang CC; Chuang JH; Hsieh CS; Lee SY; Chen CL
J Pediatr Surg; 2008 Nov; 43(11):2016-23. PubMed ID: 18970934
[TBL] [Abstract][Full Text] [Related]
25. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.
Dhaenens CM; Burnouf S; Simonin C; Van Brussel E; Duhamel A; Defebvre L; Duru C; Vuillaume I; Cazeneuve C; Charles P; Maison P; Debruxelles S; Verny C; Gervais H; Azulay JP; Tranchant C; Bachoud-Levi AC; Dürr A; Buée L; Krystkowiak P; Sablonnière B; Blum D;
Neurobiol Dis; 2009 Sep; 35(3):474-6. PubMed ID: 19591938
[TBL] [Abstract][Full Text] [Related]
26. Effect of common polymorphisms in folate uptake and metabolism genes on frequency of micronucleated lymphocytes in a South Australian cohort.
Dhillon V; Thomas P; Fenech M
Mutat Res; 2009 Jun; 665(1-2):1-6. PubMed ID: 19427504
[TBL] [Abstract][Full Text] [Related]
27. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
Skotte NH; Southwell AL; Østergaard ME; Carroll JB; Warby SC; Doty CN; Petoukhov E; Vaid K; Kordasiewicz H; Watt AT; Freier SM; Hung G; Seth PP; Bennett CF; Swayze EE; Hayden MR
PLoS One; 2014; 9(9):e107434. PubMed ID: 25207939
[TBL] [Abstract][Full Text] [Related]
28. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.
Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL
Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390
[TBL] [Abstract][Full Text] [Related]
29. Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.
Aronin N; DiFiglia M
Mov Disord; 2014 Sep; 29(11):1455-61. PubMed ID: 25164989
[TBL] [Abstract][Full Text] [Related]
30. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts.
Fink KD; Deng P; Gutierrez J; Anderson JS; Torrest A; Komarla A; Kalomoiris S; Cary W; Anderson JD; Gruenloh W; Duffy A; Tempkin T; Annett G; Wheelock V; Segal DJ; Nolta JA
Cell Transplant; 2016; 25(4):677-86. PubMed ID: 26850319
[TBL] [Abstract][Full Text] [Related]
31. Prenatal testing for Huntington's disease: a European collaborative study.
Simpson SA; Zoeteweij MW; Nys K; Harper P; Dürr A; Jacopini G; Yapijakis C; Evers-Kiebooms G
Eur J Hum Genet; 2002 Nov; 10(11):689-93. PubMed ID: 12404099
[TBL] [Abstract][Full Text] [Related]
32. Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease.
Godinho BM; Ogier JR; Darcy R; O'Driscoll CM; Cryan JF
Mol Pharm; 2013 Feb; 10(2):640-9. PubMed ID: 23116281
[TBL] [Abstract][Full Text] [Related]
33. [RNA interference and molecular pathology of selected diseases].
Lochmanová J; Bartos M
Cas Lek Cesk; 2008; 147(12):607-15. PubMed ID: 19235485
[TBL] [Abstract][Full Text] [Related]
34. Huntington's disease-like 2 in Brazil--report of 4 patients.
Rodrigues GG; Walker RH; Brice A; Cazeneuve C; Russaouen O; Teive HA; Munhoz RP; Becker N; Raskin S; Werneck LC; Junior WM; Tumas V
Mov Disord; 2008 Nov; 23(15):2244-7. PubMed ID: 18816802
[TBL] [Abstract][Full Text] [Related]
35. Huntington's disease: roles of huntingtin-interacting protein 1 (HIP-1) and its molecular partner HIPPI in the regulation of apoptosis and transcription.
Bhattacharyya NP; Banerjee M; Majumder P
FEBS J; 2008 Sep; 275(17):4271-9. PubMed ID: 18637945
[TBL] [Abstract][Full Text] [Related]
36. Review article: RNA interference--potential therapeutic applications for the gastroenterologist.
Pellish RS; Nasir A; Ramratnam B; Moss SF
Aliment Pharmacol Ther; 2008 May; 27(9):715-23. PubMed ID: 18248657
[TBL] [Abstract][Full Text] [Related]
37. Linking SNPs to CAG repeat length in Huntington's disease patients.
Liu W; Kennington LA; Rosas HD; Hersch S; Cha JH; Zamore PD; Aronin N
Nat Methods; 2008 Nov; 5(11):951-3. PubMed ID: 18931668
[TBL] [Abstract][Full Text] [Related]
38. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.
Østergaard ME; Southwell AL; Kordasiewicz H; Watt AT; Skotte NH; Doty CN; Vaid K; Villanueva EB; Swayze EE; Bennett CF; Hayden MR; Seth PP
Nucleic Acids Res; 2013 Nov; 41(21):9634-50. PubMed ID: 23963702
[TBL] [Abstract][Full Text] [Related]
39. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
Yu D; Pendergraff H; Liu J; Kordasiewicz HB; Cleveland DW; Swayze EE; Lima WF; Crooke ST; Prakash TP; Corey DR
Cell; 2012 Aug; 150(5):895-908. PubMed ID: 22939619
[TBL] [Abstract][Full Text] [Related]
40. Interference RNA technology in the treatment of CNV.
Tolentino M
Ophthalmol Clin North Am; 2006 Sep; 19(3):393-9, vi-vii. PubMed ID: 16935214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
